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Various chemical compounds are regarded 
as endocrine disruptors because they affect 
the homeostasis of the endocrine system, 
and many of these compounds are spread 
throughout the environment. Bisphenol A 
(BPA), a well-known endocrine disruptor, is 
polymerized to produce poly  carbonate plas-
tics and epoxy resins and is used in many 
industrial products. Leaching of BPA out 
of the products is increased by heating 
(Krishnan et al. 1993), contact with alka-
line substances (Olea et al. 1996), and dete-
rioration of the products (Howdeshell et al. 
2003), and BPA is thus widely released into 
the environ  ment. BPA has weak estrogenic 
activity in vivo and in vitro (Krishnan et al. 
1993; Nagel et al. 1997). Several studies have 
demon  strated adverse effects of BPA on the 
reproductive (Fernández et al. 2009), nervous 
(MacLusky et al. 2005; Rubin et al. 2006), 
and immune systems (Sawai et al. 2003).
Generally, adult animals are able to 
metabolize and eliminate BPA from the body. 
Previously, we found that BPA is highly 
glucuronidated by UGT2B1, an isoform of 
uridine 5´-diphospho-glucuronosyl  transferase 
(UGT) expressed in the rat liver (Yokota 
et al. 1999). In addition, our liver perfusion 
experiments showed that the resultant BPA-
glucuronide (BPA-GA) was excreted mainly 
in the bile (Inoue et al. 2001). Kurebayashi 
et al. (2003) showed that orally adminis  tered 
BPA is metabolized primarily into BPA-GA 
and that most BPA-GA is excreted in feces 
via bile, although some is excreted in urine. 
These findings have established that BPA is 
almost completely eliminated by the efficient 
drug-metabolizing systems of adult animals 
(glucuronidation and excretion in the bile) dur-
ing its passage through the liver. Moreover, in a 
reproductive toxicity study of three genera  tions 
of CD Sprague-Dawley rats, Tyl et al. (2002) 
found no BPA-treatment–related effects at low 
doses (0.001–5 mg/kg/day). Again, this is most 
likely attributable to efficient drug metabolism 
of xeno  biotics in an adult body.
In contrast, adverse effects of low doses of 
BPA exposure during pregnancy have been 
reported. After exposing pregnant rats to 
14C-BPA, Domoradzki et al. (2003) detected 
BPA and metabolized BPA-GA in the pla-
centa and fetus. In another study, radio  activity 
was detected in the fetal intestine and urinary 
bladder on gestational day (GD) 18 but not 
on GD12 or GD15 after pregnant rats were 
orally treated with 14C-BPA (Kurebayashi et al. 
2005). BPA exposure during the fetal and lac-
tational periods affects sexual differentiation 
of the brain structure and behavior at a dos-
age less than the human tolerable daily intake 
level (50 μg/kg; Kubo et al. 2003). In CD-1 
mice, maternal exposure to 10 μg/kg BPA/day 
induces abnormal develop  ment of the pros-
tate and urethra in male fetuses (Timms et al. 
2005). Thus, the important issues surrounding 
BPA exposure involve the adverse effects not 
only on the genera  tion exposed but also on the 
next genera  tion, when exposure occurs dur-
ing pregnancy, even at a low dose. Although a 
number of studies have found that BPA expo-
sure during pregnancy induces adverse effects 
on the next genera  tions, none have determined 
the fundamental mechanisms of these adverse 
effects. In particu  lar, the mecha  nisms of trans-
fer of BPA from mother to fetus are completely 
unknown, although this is critical to the pro-
cess that affects the next generations.
In the pregnant mother and fetus, 
the physiological state, including the drug-
metabo  lizing systems, differs from that of 
non  pregnant adult animals. Cao et al. (2002) 
reported that the hepatic expression of multi-
drug resistance-associated protein 2 (Mrp2), 
which excretes chemical conjugates such as 
glucuronide into bile duct, is reduced during 
pregnancy in the rat. Moreover, we previously 
reported that the amount of BPA-GA excreted 
in maternal veins is increased by compensa-
tory excretion (Inoue et al. 2004). This sug-
gests that the concentration of BPA-GA in 
maternal blood is increased for the entire ges-
tational period and that, consequently, there 
is an increased risk of BPA-GA transfer across 
the placenta. We have also reported that in 
fetal rats UGT activity against xeno  estrogens 
is absent and that this activity develops after 
birth, even though it is reduced in pregnant 
rats (Matsumoto et al. 2002). Thus, compared 
with the adult, the fetus has vulnerable drug-
metabolizing systems, which may explain 
adverse effects on the fetus.
BPA-GA is a biologically inactive metabo-
lite (Matthews et al. 2001), so BPA is consid-
ered to be safe once it has been conjugated to 
BPA-GA. However, during pregnancy, the 
concentration of BPA-GA in maternal blood 
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Ba c k g r o u n d: Bisphenol A (BPA), a well-known endocrine disruptor, is highly glucuronidated in 
the liver, and the resultant BPA-glucuronide (BPA-GA) is excreted primarily into bile. However, in 
rodents, prenatal exposure to low doses of BPA can adversely affect the fetus, despite the efficient 
drug-metabolizing systems of the dams. The transport mechanisms of BPA from mother to fetus are 
unknown.
oBjectives: To test our hypothesis that BPA-GA—an inactive metabolite—is passed through the 
placenta to the fetus, where it affects the fetus after reactivation, we investigated the placental transfer 
of BPA-GA and reactivation to BPA in the fetus.
Me t h o d s : After performing uterine perfusion with BPA-GA in pregnant rats, we examined the 
expression and localization of the placental transporters for drug metabolites in the perfusate by 
reverse-transcriptase polymerase chain reaction and immunohistochemistry. We also investigated the 
deconjugation of BPA-GA in the fetus and examined uridine 5´-diphospho-glucuronosyltransferase 
(UGT) activity toward BPA and the expression of UGT isoforms in fetal liver.
re s u l t s: We detected BPA-GA and deconjugated BPA in the fetus and amniotic fluid after perfusion. 
In the trophoblast cells, organic anion-transporting polypeptide 4a1 (Oatp4a1) was localized on the 
apical membrane, and multidrug resistance-associated protein 1 (Mrp1) was localized to the baso-
lateral membrane. We observed deconjugation of BPA-GA in the fetus; furthermore, we found the 
expression of UGT2B1, which metabolizes BPA, to be quite low in the fetus.
co n c l u s i o n s: These results demonstrate that BPA-GA is transferred into the fetus and deconjugated 
in the fetus because of its vulnerable drug-metabolizing system.
Key w o r d s : bisphenol A, endocrine disruptors, estrogenic compounds, metabolism, transplacental. 
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may be increased because of an increase in 
venous excretion by hepato  cytes. In the pres-
ent study, we hypothe  sized that BPA-GA is 
transferred across the placenta to the fetus and 
then adversely affects the fetus by reactivation 
to BPA. To test this hypothesis, we examined 
whether BPA-GA is passed through the pla-
centa and whether it is reactivated in the fetus.
Materials and Methods
Purification of BPA‑GA after liver perfusion. 
BPA-GA was isolated from bile obtained by 
liver perfusion using our previously described 
method (Inoue et al. 2001). Briefly, we per-
formed liver perfusion with BPA and collected 
bile. BPA-GA was then isolated from the bile 
by high-performance liquid chromatography 
(HPLC) (Shimadzu Corp., Kyoto, Japan). The 
isolated BPA-GA was dried in a freeze-drier 
(EYELA model FDU-2100; Tokyo Rikakikai 
Co. Ltd., Tokyo, Japan) and then dissolved 
in distilled water. The final concentration of 
BPA-GA was 650 μM.
Animals. Pregnant Sprague-Dawley rats 
(GD18.5) were purchased from Sankyo Lab 
Co. (Tokyo, Japan). Animals were housed 
individually under a 12/12-hr light/dark cycle 
and had ad libitum access to water and food. 
For the surgical procedure and uterine perfu-
sion, animals were treated under deep anes-
thesia with regard for alleviation of suffering. 
All experimental procedures were based on 
the guidelines of the Committee for Animal 
Welfare at Rakuno Gakuen University, which 
are based on the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory 
Animal Resources 1996). 
Surgical procedure and uterine perfusion.   
A schematic illustration of uterine perfu-
sion is shown in Figure 1A. Additional 
details of the surgical procedure are available 
in the Supplemental Material (doi:10.1289/
ehp.0901575). In this perfusion system, the 
perfusate pumped into the abdominal aorta 
is circulated through one uterine artery– 
placenta–fetus–uterine vein unit and drips 
from the drain tube inserted in the caudal vein. 
After the perfusion, dams and fetuses were 
euthanized by incision of the caudal vena cava 
under anesthesia and tissues were collected.
We used modified Krebs-Ringer’s buffer 
(mKRB; 126 mM NaCl, 3 mM KCl, 1.2 mM 
KH2PO4, 1.3 mM MgSO4, 2.4 mM CaCl2, 
10 mM glucose, 26 mM NaHCO3, 2.5% dex-
tran from Leuconostoc mesenteroides, and 3% 
Dextran 70) as the perfusate. The perfusate 
was pumped at a constant rate of 3 mL/min. 
First, we perfused four animals in a preliminary 
group with 10 μM BPA-GA for 20 min to 
determine whether BPA-GA is transferred into 
the fetus across the placenta. In this group, we 
performed a preliminary perfusion with mKRB 
for 5 min to wash away blood, followed by 
20 min inflow of mKRB containing 10 μM 
Figure 1. Uterine perfusion in the pregnant rat. (A) Schematic illustration of uterine perfusion of a 
pregnant rat. Perfusate with or without substrate flows into the abdominal aorta of the mother and cir‑
culates through the target placenta and fetus; the perfusate then returns to the caudal vena cava and 
is recovered from the drain tube. (B–D) Identification of BPA‑GA purified from bile after liver perfusion, 
shown by selected ion monitoring (SIM) mass chromatograms. Using LC/TOF‑MS, we confirmed the 
molecular mass of BPA‑GA (B) and the absence of contamination with BPA (C), and we analyzed the 
BPA standard (D). (B) SIM mass chromatogram at m/z = 403 of the purified BPA‑GA used in the present 
study; the inset shows the mass spectrum of purified BPA‑GA. (C) SIM mass chromatogram (m/z = 227) 
of the substrate showing no contamination with BPA. (D) SIM mass chromatogram (m/z = 227) of the 
BPA standard. 
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BPA-GA. After the perfusion, the fetus and 
amniotic fluid were collected. 
To elucidate the kinetics of perfused 
BPA-GA, we used another group of four ani-
mals to compare the amount of BPA-GA in 
maternal veins with that in fetal tissue. After 
preliminary perfusion with mKRB for 5 min, 
pregnant rats were perfused with mKRB con-
taining 2 μM BPA-GA for 20 min. Then, 
mKRB without BPA-GA was perfused for 
70 min (a total of 90 min). From the begin-
ning of the BPA-GA perfusion, the perfusate 
that drained from the caudal vena cava was 
collected from each animal at 5-min intervals 
for 90 min. At the end of perfusate collection, 
the fetus, amnion, amniotic fluid, uterus, and 
placenta were collected. We also performed a 
control study using 1-naphthol-glucuronide 
(1-NA-GA; Nacalai Tesque Inc., Kyoto, 
Japan) as the substrate. Four pregnant rats 
were used in each perfusion group. Values are 
expressed as mean ± SE.
HPLC and liquid chromatography/time‑
of‑flight mass spectrometry (LC/TOF‑MS) 
analysis. Perfusates collected from the caudal 
vena cava were collected after uterine perfusion 
and prepared for HPLC and LC/TOF-MS 
analysis. Each perfusate sample was mixed 
with a 4-fold volume of acetonitrile and cen-
trifuged at 13,000 rpm for 5 min at 4°C; each 
supernatant was then analyzed by HPLC.
To prepare tissues for HPLC and 
LC/TOF-MS analysis, we first added each 
sample to 0.3 mL methanol; the sample was 
homoge  nized and then sonicated for 5 min. 
The products were centrifuged at 13,000 rpm 
for 5 min at 4°C, and the supernatants were 
concentrated by solid-phase extraction using 
an Oasis HLB Plus cartridge (Waters Corp., 
Milford, MA, USA). The extracts were then 
analyzed by HPLC.
We used an HPLC system (Tosoh Corp.,   
Tokyo, Japan) that consisted of a dual 
pump (DP-8020), a fluorescent photometer 
(FS-8020), and a column oven (CO-8020). 
Samples were separated at 40°C using a reverse-
phase column (Unison UK-C18; Imtakt Corp., 
Kyoto, Japan) at a flow rate of 1.0 mL/min 
under a linear gradient of solution A (methanol/ 
water = 24/76 vol/vol with 10 mM ammonium 
acetate) and solution B (methanol) for 20 min. 
BPA-GA was detected at excitation/emission 
of 275/308 nm and 1-NA-GA was detected at 
excitation/emission of 283/336 nm. The results 
were recorded using LC-8020 integration soft-
ware (Tosoh Corp.); the elution peaks of BPA 
and BPA-GA were noted and the concentra-
tions compared with the standards.
LC/TOF-MS was performed using the 
HPLC system described above and LCT pre-
mier XE (Waters Corp.). The flow rate of 
HPLC was 0.3 mL/min, and BPA-GA was 
monitored at m/z 403–404 by TOF-MS. In 
the present study, the limits of detection of 
BPA and BPA-GA in LC/TOF-MS were both 
20 pmol/mL (data not shown).
Antibodies. A23 anti-Mrp1 polyclonal 
antibody (Alexis Biochemicals) was purchased 
from Enzo Life Sciences Inc. (Plymouth 
Meeting, PA, USA). We obtained anti–organic 
anion-transporting polypeptide (anti-Oatp4a1) 
polyclonal antibody from Scrum, Inc. (Tokyo, 
Japan); anti-Oatp4a1 is designed to recognize 
the amino acid sequence LPSQSSA, which 
is common between human and rat (human, 
705–711; rat, 703–709). 
Immunohistochemical analysis. Placental 
tissue samples were analyzed by immuno-
histo  chemistry, as described in detail in 
the Supplemental Material (doi:10.1289/
ehp.0901575). Briefly, tissue sections were 
incubated with anti-Oatp4a1 antibody or 
anti-Mrp1 antibody and analyzed with a con-
focal laser scanning microscope (Axionvert 
200M) and PASCAL software (Carl Zeiss 
Microimaging GmbH, Jena, Germany). 
Total RNA isolation and synthesis of 
cDNA. Maternal liver, placenta, fetal liver, 
and fetal intestine were collected on GD18.5. 
Total RNA was isolated from the tissues using 
the RNeasy Mini Kit (Qiagen, Heidelberg, 
Germany) according to the manufacturer’s 
instructions. cDNA was synthesized from total 
RNA using Superscript III (Invitrogen Corp., 
Carlsbad, CA, USA) reverse transcriptase 
according to the manufacturer’s instructions.
Primers. Sequences of the oligonucleo-
tide primers to amplify gene-specific cDNAs 
are available in the Supplemental Material 
(doi:10.1289/ehp.0901575).
Figure 2. Analysis of the tissues collected after uterine perfusion. (A) Time schedule of the preliminary 
uterine perfusion with 10 μM BPA‑GA for 20 min. (B and C) HPLC profiles of the extract from amniotic fluid 
after uterine perfusion (B) and standard solution containing 5 μM BPA‑GA and BPA (C). Black arrowheads 
indicate BPA‑GA, and gray arrows indicate BPA. (D) Identification of BPA‑GA in standard solution (5 μM 
BPA‑GA; top) and in the extract from the fetus and amniotic fluid after perfusion, detected by LC/TOF‑MS. 
Left, LC chromatograms; right, mass spectra. Black arrowheads indicate BPA‑GA. 
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Quantitative reverse‑transcription poly‑
merase chain reaction (RT‑PCR). Quantitative 
expression of Mrp1, Mrp2, and Oatp4a1 mRNA 
in maternal liver and placenta was investigated 
by real-time RT-PCR using the QuantiTect 
SYBR Green PCR kit (Qiagen) and analyzed by 
iQ5/MyiQ Single-Color (Bio-Rad Laboratories 
Inc., Hercules, CA, USA). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used 
as the internal standard. The copy number of 
each transporter gene was divided by that of 
GAPDH for normali  zation. Quantitative val-
ues are mean ± SE of four amplifications for 
placenta and three for maternal liver for each 
transporter gene.
Incubation of fetal primary cell cultures 
with BPA‑GA. Fetal liver and heart tissues, 
collected on GD18.5, were washed twice with 
cold phosphate-buffered saline (PBS). Tissues 
for two fetuses were combined in one tube 
and then minced in cold PBS and centrifuged 
for 5 min at 100 × g at 4°C. After removing 
the supernatant, the pellets were resuspended 
in 5 mL William’s medium (Sigma-Aldrich, 
Inc., St. Louis, MO, USA) containing collage-
nase (350 U; Wako Pure Chemical Industries, 
Ltd., Osaka, Japan) and DNase I (375 U; 
Roche Diagnostics, Basel, Switzerland) and 
incubated for 30 min at 37°C. After the incu-
bation, samples were centrifuged for 5 min 
at 100 × g at 4°C, and the supernatants were 
removed. The remaining cells, which had been 
isolated from two fetuses, were resuspended 
in 200 μL William’s medium with or without 
25 μM BPA-GA and incubated at 37°C for 
10, 30, 60, or 120 min. At each time point, 
cells and medium were pooled and extracts 
were prepared for HPLC as described above, 
by adding the same volume of methanol. All 
experiments were repeated five times. Values 
express the mean ± SE.
UGT enzyme analysis. We examined UGT 
enzymatic activity using hepatic microsomes. 
We prepared the microsomes from rat liver 
and performed UGT enzyme analysis as 
described previously by Daidoji et al (2006). 
See the Supplemental Material (doi:10.1289/
ehp.0901575) for details.
Results
Passage of BPA‑GA through the placenta. First, 
we performed uterine perfusion (Figure 1A) 
using BPA-GA in pregnant rats at GD18.5 to 
elucidate whether BPA-GA, a major metabo-
lite in the maternal body, can pass through the 
placenta into the fetus. We previously demon-
strated the kinetics of various endocrine dis-
ruptors by perfusion techniques using target 
organs (Inoue et al. 2001; Narukawa et al. 
2004). These techniques enable us to moni-
tor the kinetics of substrates under conditions 
similar to the physiological state. Uterine per-
fusion can also mimic the original physiologi-
cal state of the pregnant mother. The purity 
of BPA-GA isolated from perfusate after liver 
perfusion with BPA was confirmed by LC/
TOF-MS (Figure 1B). Some studies have 
shown that a small amount of BPA-GA is 
transferred into the fetus by maternal exposure 
to BPA during pregnancy (Domoradzki et al. 
2003). Therefore, we performed a preliminary 
uterine perfusion experiment (20-min inflow 
with 10 μM BPA-GA; Figure 2A). After the 
perfusion, we detected BPA-GA (Figure 2B, 
arrowhead) and deconjugated BPA (Figure 2B, 
gray arrow) in the fetus and amniotic fluid by 
HPLC and confirmed detection of BPA-GA 
by LC/TOF-MS (Figure 2D, arrowheads). 
Next, to examine the kinetics of BPA-GA 
in the maternal–placental–fetal unit, we per-
formed perfusion for 20-min inflow with a 
lower concentration (2 μM) of BPA-GA and 
additional inflow without BPA-GA for 70 min 
(total perfusion time, 90 min; Figure 3A). We 
also performed a control study using 1-NA-GA 
as the substrate; a total of 120 nmol substrate 
was used for the 20-min perfusions. After the 
90-min perfusion, we detected almost all of the 
BPA-GA and 1-NA-GA in the perfusate col-
lected from the maternal vein (Figure 3B and 
Table 1). As shown in Table 1, BPA-GA was 
also detected in the fetus. Moreover, deconju-
gated BPA was detected in amniotic fluid and 
in the fetus. In the fetus, we detected about 
0.09% of the total amount of BPA-GA. Thus, 
the kinetic study detected BPA-GA and BPA in 
fetal tissues, although in small amounts. In con-
trast, we did not detect 1-NA-GA or deconju-
gated 1-NA except in the perfusate (Figure 3C), 
indicating that the placental barrier was work-
ing in this perfusion system. These data demon-
strate that in this system only BPA-GA passed 
through the placenta into the fetus.
Expression and localization of placental 
transporters. The uterine perfusion experiment 
showed that only BPA-GA was transferred 
Figure 3. The kinetics of BPA‑GA in the maternal–placental–fetal unit after uterine perfusion. (A) Time 
schedule of uterine perfusion with 2 μM BPA‑GA; an additional perfusion without BPA‑GA was performed 
for 70 min after a 20‑min perfusion with BPA‑GA. (B) Time course of concentration of BPA‑GA in the col‑
lected perfusate; after 70 min, BPA‑GA was barely detected in the perfusate (n = 4). 
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Table 1. Distribution of the substrate after perfusion, shown as the amount (mean ± SD) of substrate 
detected in each sample. 
Substrate
BPA‑GA 1‑NA‑GA
Tissues BPA‑GA BPA 1‑NA‑GA 1NA
Perfusate (maternal side)  113.10 ± 6.92 nmol ND 111.77 ± 2.58 nmol ND
Uterus ND ND ND ND
Placenta ND ND ND ND
Amnion ND ND ND ND
Amniotic ﬂuid ND 31.35 ± 4.52 pmol ND ND
Fetus 109.26 ± 36.75 pmol 6.45 ± 1.45 pmol ND ND
ND, not detected. The total amount of substrate detected in sample was calculated from the area under the curve shown 
in Figure  3B. n = 4 for each tissue type per treatment group. Nishikawa et al.
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across the placenta into the fetus. This selec-
tive transfer indicates the involvement of pla-
cental transporters. Thus, we examined the 
expression and localization of the placental 
transporters that would possibly mediate the 
transfer of BPA-GA. Some members of the 
Oatp and Mrp families are known to trans-
port the glucuronide conjugate of steroid 
hormones, which structurally resemble BPA. 
Therefore, we focused on these two trans-
porter families.
First, we examined the expression of the 
Oatp and Mrp families in the placenta and 
maternal liver on GD18.5 by RT-PCR. In the 
placenta, we detected high levels of Mrp1 and 
Oatp4a1 expression (Figure 4A). In mater-
nal liver, we detected Mrp2, Oatp1a4, and 
Oatp1b2 expression (Figure 4A). Quantitative 
RT-PCR confirmed the high levels of Mrp1 
and Oatp4a1 expression in the placenta and 
showed that Mrp2 was highly expressed in 
maternal liver (Figure 4B). These data suggest 
that Oatp4a1 and Mrp1 play an important 
role in the transport of BPA-GA from mater-
nal blood to the fetus.
Mrp1 is an efflux transporter, whereas 
Oatp4a1 is an influx transporter. To examine 
the possibility of BPA-GA being transferred 
across the placenta by these transporters, we 
examined localization of Mrp1 and Oatp4a1 
in the placenta by immuno  histo  chemical 
analysis. The arrowheads in Figure 5B indi-
cate trophoblast cells, which separate maternal 
blood from fetal blood vessels. Oatp4a1, an 
influx transporter, was localized on the apical 
membrane of the trophoblast cells (Figure 5D 
and arrows in Figure 5E). In contrast, Mrp1, 
an efflux transporter, was localized on the 
basolateral membrane of the trophoblast cells 
(Figure 5G and arrows in Figure 5H). Both 
Mrp1 and Oatp4a1 are known to transport 
endogenous estrogen conjugates, such as 
dehydro  epi  andro  sterone-sulfate (DHEAS) and 
17β-estradiol-glucuronide. These localization 
patterns suggest that BPA-GA is transferred 
into tropho  blast cells from maternal blood 
vessels by Oatp4a1 and is then excreted into 
fetal blood from the trophoblasts by Mrp1.
Deconjugation of BPA‑GA in the fetus. In 
the uterine perfusion experiment, BPA-GA 
passed through the placenta and was detected 
in the fetus. Moreover, we detected decon-
jugated BPA in the fetus and amniotic fluid 
after the perfusion (Figure 3C). These results 
suggest that fetal tissues have the ability to 
deconjugate BPA-GA. To determine the fate 
of BPA-GA in the fetus, we examined decon-
jugation of BPA-GA in vitro. We observed 
deconjugation of BPA-GA in fetal liver cells 
in a time-dependent manner and to a much 
smaller degree in fetal heart cells (Figure 6A); 
however, we detected the expression of 
β-glucuronidase (β‑Gase), which deconju-
gates glucuronide conjugates, in both tis-
sues (Figure 6B). These results indicate that 
BPA-GA is deconjugated to BPA in the fetus.
Metabolism of BPA in the fetus. In a previ-
ous study (Matsumoto et al. 2002), we found 
that, compared with adult liver, the fetus has 
only a few UGT activities that glucuronidate 
endogenous steroid hormones and xeno  biotics. 
This low level of UGT activity may induce 
delay of metabolism toward deconjugated BPA 
in the fetus. To examine this possibility, we 
determined the mRNA expression levels of the 
UGT isoforms in maternal liver and fetal tissue 
by RT-PCR. In the fetal tissues, the expres-
sion of UGT2B1 was much lower than that 
in maternal liver (Figure 6C). These results 
are consistent with the study of Matsumoto 
et al. (2002). We also previously reported that 
UGT2B1 plays an important role in glucuroni-
dation of BPA (Yokota et al. 1999). In contrast, 
other UGT isoforms examined were expressed 
in the fetus. UGT activities toward BPA were 
quite low in fetal liver microsomes compared 
with those in the mother, although UGT activ-
ities toward 1-NA were about 60% in maternal 
microsomes (Figure 6D). Taken together, the 
experiments in the present study indicate that 
the fetus has low ability to glucuronidate BPA.
Discussion
In the present study, we found that BPA-GA 
passes through the placenta and is deconju-
gated to BPA in the fetus. To our knowledge, 
this is the first study to demonstrate the pla-
cental transfer of BPA-GA itself and the reac-
tivation of BPA-GA to BPA in the fetus.
BPA-GA has long been considered to be 
an inactivated, safe metabolite that is eventu-
ally and inevitably excreted from the body. 
In addition, the placenta has been thought 
to act as a barrier for the fetus against xeno-
biotics, such as drugs and other chemical com-
pounds. However, in the uterine perfusion 
experiments in the present study, the kinetic 
data for BPA-GA after perfusion indicate 
that although the placenta mostly protects 
the fetus from exposure to BPA-GA, a small 
amount of BPA-GA is in fact transferred 
into the fetus from maternal blood vessels via 
the placenta (Figure 3C). Domoradzki et al. 
(2003) demon  strated that the concentra-
tion of BPA-GA in the fetus is approximately 
0.1% compared with that in maternal plasma 
after oral administration of 10 mg/kg BPA 
to GD16.0 rat mothers. Kurebayashi et al. 
(2005) also detected radioactivity in GD18 
fetal tissues 24 hr after oral administration of 
14C-BPA to the pregnant rats, but they found 
no radioactivity in fetuses on GD13 or GD15. 
The kinetics of the present study support these 
findings that a small amount of BPA-GA is 
transferred to fetus during late pregnancy.
In the present study, we detected a small 
amount of BPA-GA and deconjugated BPA in 
fetal tissues after perfusion with 2 μM BPA-GA. 
This perfused concentration is much higher 
than would be expected in a realistic situa  tion, 
therefore, because the level of substrate that 
transfers to the fetus is low, we performed the 
perfusion using a high concentration of sub-
strate for effective detection by the HPLC fluo-
rescence photometer. The important result of 
the perfusion experiment is that BPA-GA was 
transferred across the placenta into the fetus, 
whereas 1-NA-GA was not. The difference in 
placental transfer of these substrates demon-
strated that the placental function was reliable 
in this perfusion system. We believe that our 
findings suggest that humans may be exposed 
to BPA in utero, despite the fact that our experi-
ments involved much higher exposure levels 
Figure 4. Mrp and Oatp isoforms expressed in the placenta (P) and maternal liver (ML) at GD18.5. (A) Expression of Mrp and Oatp isoforms examined by RT‑PCR. 
(B) Quantitative analysis of Oatp4a1, Mrp1, and Mrp2 mRNA relative to GAPDH (n = 4). 
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that would occur under realis  tic conditions. We 
previously reported that the excretion rate of 
BPA-GA from the liver into bile is decreased 
and that compensatory excretion of BPA-GA 
into the hepatic vein is increased in rodents 
during pregnancy (Inoue et al. 2004), and we 
hypothe  size that this may also occur in humans. 
When coupled with the relatively long gestation 
period in humans, such compensatory increases 
in plasma BPA-GA could increase the risk of 
placental transfer of BPA-GA, even though 
maternal exposures may be low.
Another intriguing point is substrate speci-
ficity for placental transfer of metabolite. In 
the uterine perfusion with 1-NA-GA (also a 
type of conjugate with glucuronic acid), we did 
not detect 1-NA-GA or deconjugated 1-NA 
in the placenta or fetal tissues (Figure 3C). 
These results suggest that placental trans-
fer of BPA-GA occurs in a selective manner. 
BPA-GA is a more hydro  philic compound than 
BPA, which raises the possibility that BPA-GA 
is transferred across the placenta in a positive 
manner via placental transporters. During 
pregnancy, nutrition and other endogenous 
chemi  cal compounds are supplied to the fetus 
via the placenta, and metabolic waste products 
and xeno  biotics are excreted into the maternal 
blood through the placenta. Thus, during preg-
nancy, numerous kinds of transporters that 
mediate the transfer of each compound are 
predicted to be expressed in the placenta. 
Various transporters that either excrete 
drugs from the fetus to maternal blood or 
transfer nutrition and physiological com-
pounds from the maternal body to the fetus 
have been isolated and charac  terized. Some of 
these transporters recognize xeno  biotics because 
of their structural resemblance to physiological 
compounds. Generally, endocrine-disrupting 
chemicals, including BPA, often mimic endog-
enous chemical compounds such as estrogen. 
Moreover, the placenta produces steroid hor-
mones that are used in both the mother and 
fetus (Strauss et al. 1996). Therefore, BPA-GA 
may be transferred across the placenta into the 
fetus by placental transporters that mediate 
transfer of essential endogenous physiologi-
cal estrogenic compounds. Some members 
of the Oatp and Mrp transporter families are 
Figure 6. Metabolism of BPA‑GA in the fetus. 
Abbreviations: H, fetal heart; L, fetal liver; ML, 
maternal liver; P, placenta. (A) Time course showing 
concentration of deconjugated BPA (mean ± SE) 
in the extract of cultured fetal liver and heart cells 
(see “Materials and Methods” for details; n = 5). 
(B) Expression of β-Gase in the fetal liver and heart 
on GD18.5 by RT‑PCR. (C) Expression of UGT iso‑
forms in ML, P, L, and I determined by RT‑PCR. 
(D) UGT enzymatic activity toward BPA or 1‑NA in 
fetal or maternal hepatic microsomes. Values shown 
are the concentration (mean ± SE) of glucuronide 
conjugates in microsome protein (nmol/μg) after 
30‑min reaction time (n = 5).
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Figure 5. Localization of Oatp4a1 and Mrp1 in rat placenta. (A and B) Photomicrographs showing the 
structure of the rat placenta on GD18.5 (stained with hematoxylin and eosin). (A) Higher magnification of 
the placenta section shown in the boxed area of the inset). (B) Higher magnification of the boxed region in 
A; trophoblast cells (arrowheads) are localized between a fetal blood duct (asterisk) and maternal blood. 
In A and B, bars = 200 μm; in the inset of A, bar = 1 mm. (C–E) Immunofluorescence staining of placenta 
with (D and E) or without (C) Oatp4a1 antibody (green signal). (F–H) Immunofluorescence staining of 
placenta with (G and H) or without (F) Mrp1 antibody (green signal). In (C–H), nuclei are stained with pro‑
pidium iodide (red); arrows indicate trophoblasts in E and H, and asterisks (*) indicate fetal blood vessels. 
Bars = 50 μm in C–H. 
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known to transport conjugates of steroid hor-
mones such as DHEAS and 17β-estradiol-
glucuronide, suggesting that BPA-GA is 
transported across the placenta by these trans-
porters. In the present study, we observed high 
expression of Oatp4a1 and Mrp1 in the pla-
centa by quantitative RT-PCR. High expres-
sion levels of Oatp4a1 and Mrp1 in rat placenta 
have been also reported by Leazer and Klaassen 
(2003). Our immuno  histo  chemical analysis 
revealed that Oatp4a1 localizes on the api-
cal membrane of trophoblast cells, and Mrp1 
on the basolateral membrane. These localiza-
tions are coincident with those in humans, as 
reported for Oatp4a1 by Sato et al. (2003) and 
for Mrp1 by Nagashige et al. (2003). Oatp4a1 
mediates influx transport, and Mrp1 medi-
ates efflux transport. In view of these results, 
BPA-GA in maternal blood may be taken up 
by trophoblast by Oatp4a1 and then trans-
ferred into the fetus by Mrp1. 
Some reports have indicated that cellular 
transfer of 1-NA-GA is mediated by the MRP 
family (de Vries et al. 1989; Strazielle and 
Ghersi-Egea 1999), but affinity of 1-NA-GA 
toward these transporters is still unknown. 
We think that the substrate specificity of 
Oatp4a1, which is the first trigger of influx 
transport, may be relevant to the selective 
transfer of these substrates into the fetus. Ugele 
et al. (2002) reported that the OATP family 
expressed abundantly in the human placenta 
(e.g., OATP-B, OATP-D, OATP-E) tended 
to have substrate affinity toward steroid sulfate, 
although OATP-E (an Oatp4a1 homolog) also 
had affinity toward tauro  cholate. These authors 
also demonstrated that uptake of DHEAS by 
monolayer tropho  blast was not influenced by 
1.2 mM SO4
2– in the transport buffer, indicat-
ing that SO4
2– is not an inhibitor/substrate 
of the steroid sulfate transporters and that the 
carbon backbone of the steroid sulfates is a pre-
requisite for inhibition/transport. The selective 
transport between BPA-GA and 1-NA-GA, 
both glucuronide conjugates, could result from 
the difference in affinity not only for the con-
jugate residue but also for the parent residue. 
Further study is required to confirm the affin-
ity of BPA-GA to these transporters. Placenta-
specific expression of Oatp4a1 has already 
been reported (Cheng et al. 2005; Leazer and 
Klaassen 2003); however, the physiological 
role of Oatp4a1 in the placenta is still unclear. 
Analysis of the functions of Oatp4a1 will lead 
to greater understanding of this molecule’s 
placental functions regarding the synthesis, 
metabolism, and kinetics of hormones. 
In the present study, we confirmed the 
purity of BPA-GA obtained from bile after 
liver perfusion using LC/TOF-MS (Figure 1B). 
Nevertheless, we detected not only BPA-GA 
but also deconjugated BPA in the fetus and 
amniotic fluid after uterine perfusion. The 
detection of BPA indicates the possibility that 
BPA-GA is deconjugated by fetal β-Gase. 
Certain organs, such as the lung, small intes-
tine, and placenta, have high β-Gase activity, 
which causes release of glucuronic acid from a 
glucuronide conjugate (Paigen 1989; Sperker 
et al. 1997). Thus, we examined the possibility 
of deconjugation of BPA-GA in fetal tissue. 
After co-incubation with BPA-GA, we 
detected deconjugated BPA in fetal liver and 
to a small degree in fetal heart (Figure 6A). 
We observed β‑Gase expression in both tis-
sues (Figure 6B). Interestingly, St-Pierre et al. 
(2004) reported that the expression of Oatp4a1 
in fetal liver is approximately 105 times higher 
than that in adult liver, although this expres-
sion level is still very low compared with pla-
centa. The difference in deconjugation rates 
among tissues in the present study may reflect 
uptake into cells via transporters rather than 
through β-Gase expression. Another possibility 
is that BPA-GA is deconjugated in the placenta 
and then resultant BPA is transferred into the 
fetus by passive diffusion. Therefore, we also 
examined deconjugation of BPA-GA in placen-
tal tropho  blast primary cell culture. We did not 
observe deconjugation in the trophoblast cells, 
but we did observe β‑Gase expression (data not 
shown). The possibility of transfer of placen-
tal deconjugated BPA could not be excluded 
completely in this experiment. Further work is 
required to examine the tissue-specific decon-
jugation of BPA-GA and the possibility of BPA 
transfer. At any rate, these data demonstrate 
that once BPA-GA is transferred into the fetus, 
it is deconjugated (reactivated) to BPA, and 
that this may be due to uptake of BPA-GA 
into fetal cells by transporters and subsequent 
catalysis by β-Gase.
When contemplating whether decon-
jugated BPA adversely affects the fetus, it is 
most important to consider the fetal drug- 
metabolizing system, especially in relation 
to UGT2B1 activity, which glucuronidates 
BPA to BPA-GA (Yokota et al. 1999). UGT 
isoforms glucuronidate endogenous physio-
logi  cal compounds and other xeno  biotics 
(Webb et al. 2005). We previously reported 
that UGT activity in the fetus is quite 
low, compared with that in the adult, and   
develops gradually after birth (Matsumoto 
et al. 2002). In the present study, the expres-
sion of UGT2B1 mRNA in fetal organs 
was much lower than that in maternal liver. 
Moreover, in the UGT activity assay using 
liver microsomes on GD18.5, UGT activi-
ties in the fetal liver microsomes toward BPA 
were quite low. In this experiment, the ratio 
of fetal UGT activity toward BPA was about 
20% of maternal microsomes (Figure 6D). 
However, we also previously showed that the 
UGT activity toward BPA in pregnant rats on 
GD19.0 were decreased to about 70% of that 
of non  pregnant adult rats (Matsumoto et al. 
2002). Therefore, in theory, the fetal UGT 
activity toward BPA during late pregnancy 
may be < 15% of that in non  pregnant adult 
rats. On the other hand, the fetal UGT activ-
ity toward 1-NA was higher than that toward 
BPA, and we observed abundant expression of 
UGT1A6, which is known to glucuronidate 
1-NA, in fetal tissues. Although we observed 
the expression of other UGT isoforms, such 
as UGT1A1, UGT1A6, and UGT1A7, in the 
fetus (Figure 6C), the results of the UGT activ-
ity assay strongly suggested that the fetus has 
low ability to metabolize BPA due to a defi-
ciency in UGT2B1. UGT2B1 has also been 
shown to glucuronidate some xeno  biotics such 
as 4-hydroxybiphenyl and opioid compounds 
(King et al. 1997). This suggests that there 
are different risks to the fetus according to the 
xeno  biotic involved. In particular, exposure to 
Figure 7. The predicted mechanism of adverse effects on the fetus induced by maternal BPA exposure 
during pregnancy. BPA‑GA in the maternal blood is transferred across the placenta to the fetus and then 
deconjugated to BPA. Deconjugated BPA may remain in the fetus because of a deficiency in fetal UGT 
activities.
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chemical compounds that are glucuronidated 
by UGT2B1 is critical for the fetus.
A series of results in the present study 
suggest that the fate of some glucuronide-
conjugated chemical compounds in the mater-
nal body may be similar to that of BPA-GA 
during pregnancy. Once the glucuronide-
conjugate is transferred into the fetus and 
deconjugated, it may be difficult to protect the 
fetus from exposure to reactivated chemi  cals 
because of its vulnerable drug-metabolizing 
system (Figure 7). The glucuronide conjugate 
was previously considered to be inactive and 
therefore non  toxic. Therefore, when we assess 
the toxicity of xeno  biotics, it is important 
to consider the placental transfer of inactive 
metabolites such as BPA-GA.
Rodent placenta, including rat, is used 
as a model of human placenta because of its 
structural similarities (placenta hemo  chorialis). 
There are, however, some important differ-
ences between rodent and human placental 
structure. In rodents, maternal blood and fetal 
blood vessels are primarily separated by two 
syncytio  trophoblast layers, but in humans, 
only a syncytio  trophoblast monolayer sepa-
rates fetal blood vessels from maternal blood 
(Malassiné et al. 2003). Therefore, it is pos-
sible that the human fetus is more sensitive 
and at greater risk than is the rodent fetus.
In human liver microsomes, UGT2B15 
is a major isoform that glucuronidates BPA 
(Hanioka et al. 2008). Moreover, Strassburg 
et al. (2002) observed that in human fetal 
liver at 20 weeks gestation, UGT2B15 was 
not expressed as well as other UGT isoforms 
examined. Both of these studies also suggest 
that human fetuses also have metabolizing 
systems vulnerable to BPA.
Conclusion
Our study had three major findings. First, 
BPA-GA is transferred into the fetus through 
the placenta, even if only in small amounts. 
Second, BPA-GA is deconjugated to BPA in 
the fetus. Third, fetal liver microsomes have 
low ability to metabo  lize BPA to BPA-GA, as 
supported by the low expression of UGT2B1 
in the fetus. BPA may have been detected 
in the fetus after the perfusion due to high 
deconjugation ability of BPA-GA and low 
UGT activity toward BPA. Thus, we hypothe-
size that prenatal exposure to BPA may occur 
at levels sufficient to influence fetal develop-
ment because of the exceptional drug-metabo-
lizing system of the mother and fetus, which 
is particular to pregnancy. In 2003, 6 bil-
lion pounds of BPA were produced world-
wide (Burridge 2003). Furthermore, BPA has 
been shown to be easily released from prod-
ucts. Therefore, it is impossible to completely 
protect pregnant women from exposure to 
BPA. However, understanding the mechanism 
by which BPA-GA transfers across the pla-
centa may allow protection of the fetus from 
exposure to BPA and its metabolites. Further 
study is necessary to elucidate the process of 
BPA-GA transfer across the placenta.
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